These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Characterization of chemotherapy-induced morphonuclear modifications in the P388 leukaemia and the MXT mammary tumour models of the mouse. Budel V, Pauwels O, Francisco J, Gasperin P, Pasteels JL, Kiss R. J Cancer Res Clin Oncol; 1995 Aug; 121(2):89-97. PubMed ID: 7883781 [Abstract] [Full Text] [Related]
32. Effect of guanosine on antitumor activity of fluorinated pyrimidines against P 388 leukemia. Iigo M, Hoshi A. Cancer Chemother Pharmacol; 1984 Oct; 13(2):86-90. PubMed ID: 6235977 [Abstract] [Full Text] [Related]
36. In vivo response of mitoxantrone and doxorubicin with dipyrone in parental and doxorubicin-resistant P388 leukemia. Kamath NS, Chitnis MP. Oncology; 1990 Oct; 47(2):166-9. PubMed ID: 2314829 [Abstract] [Full Text] [Related]
37. Circumvention of multidrug resistance in P388 murine leukemia cells by a novel inhibitor of cyclic AMP-dependent protein kinase, H-87. Miyamoto K, Wakusawa S, Nakamura S, Koshiura R, Otsuka K, Naito K, Hagiwara M, Hidaka H. Cancer Lett; 1990 May 15; 51(1):37-42. PubMed ID: 2337896 [Abstract] [Full Text] [Related]
39. Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]- sulfatoplatinum(II), a new compound for the treatment of the mammary carcinoma. Gust R. Arch Pharm (Weinheim); 1994 Jan 15; 327(1):49-54. PubMed ID: 8117188 [Abstract] [Full Text] [Related]